How much funding has Kano Therapeutics raised?

Kano Therapeutics has raised $7.2M in total funding, most recently a Seed round.

Who are Kano Therapeutics's investors?

Kano Therapeutics's investors include The Engine.

When was Kano Therapeutics founded?

Kano Therapeutics was founded in 2022.

Where is Kano Therapeutics headquartered?

Kano Therapeutics is headquartered in Cambridge, United States.

What industry is Kano Therapeutics in?

Kano Therapeutics operates in Biotech, Healthcare.

How many employees does Kano Therapeutics have?

Kano Therapeutics has 1-10 employees.

Kano Therapeutics

The DNA platform for genetic medicine

Cambridge, United States · Founded 2022 · $7.2M raised

Biotech

Healthcare

Headquarters: Cambridge
Employees: 1–10
Founded: 2022
Business Model: B2B

Website: kanotherapeutics.com
Total Funding: $7.2M
Last Round: $7.2M SeedMay 2024
Rounds: 1

About

Kano Therapeutics is a Cambridge, Massachusetts biotech developing circular single-stranded DNA (cssDNA) as a next-generation genetic medicine payload, offering a high-fidelity, immune-quiet, and scalable alternative to viral vectors and toxic double-stranded DNA. The platform supports CRISPR-based knock-ins, targeted insertion with recombinase or transposon systems, and non-integrating episomal expression, manufactured at industrial scale via fermentation. Kano partners with cell and gene therapy developers, supplying DNA products from early evaluation through GMP production.

Summary

Kano Therapeutics is a Biotech company based in Cambridge, United States, founded in 2022. It has raised $7.2M in total across 1 round, most recently a $7.2M Seed round in May 2024. Investors include The Engine.